Abstracts tagged "Drug toxicity"

Abstract Number: 2507 • ACR Convergence 2025
Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)
Camille Mettler¹, Laurent Chouchana² and Benjamin Terrier³, ¹Département de Médecine interne, Hôpital Bichat-Claude-Bernard, Paris, France, ²Département de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Cochin, Paris, France, ³Cochin Hospital, Paris, France
Background/Purpose: Avacopan, an oral C5aR antagonist, is approved for the treatment of ANCA-associated vasculitis (AAV) as a steroid-sparing alternative. While clinical trials demonstrated a positive…
Abstract Number: 1116 • ACR Convergence 2025
Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
Sarah Sun¹, Cathryn Lee² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chicago, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) used for cancer therapy can have varied toxicities among which pneumonitis (ICI-pneumonitis) is a rare (< 5%) but often fatal…
Abstract Number: 2276 • ACR Convergence 2025
Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
Jennifer Hanberg¹, David Cheng², Xuan Wang³, Rahul Sangar⁴, Yuk-Lam Ho⁴, Lauren Costa⁴, Rachael Matty⁴, Candace Feldman¹, Tate Johnson⁵, Joshua Baker⁶, Bryant England⁵, J. Michael Gaziano¹, Kelly Cho⁷, James O'Dell⁵, Grant Cannon⁸, Paul Monach⁴, Ted Mikuls⁵, Tianxi Cai⁷ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³University of Utah, Salt Lake City, UT, ⁴VA Boston Healthcare System, Boston, MA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Harvard Medical School, Boston, MA, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are often avoided when treating rheumatoid arthritis (RA) patients with decompensated heart failure (HF), based on increased rates of…
Abstract Number: 1112 • ACR Convergence 2025
Breaking Bones, Breaking Hearts: A FAERS Perspective on Osteoporosis Medications
Manush Sondhi¹, Namrata Singh², Julie Carkin¹ and Grant Hughes³, ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA, ³University of Washington, Lynnwood, WA
Background/Purpose: The cardiovascular risks associated with osteoporosis medications remain incompletely understood. Previous studies suggest that romosozumab (ROM) is most strongly associated with major adverse cardiovascular…
Abstract Number: 2269 • ACR Convergence 2025
Key factors in optimizing the dose of Baricitinib in rheumatoid arthritis: a study based on routine clinical practice and its therapeutic implications
Daniel Campos-Martin¹, Nerea Alcorta-Lorenzo², César Antonio Egües Dubuc², Luis Maria Lopez-Dominguez³, Lucia Otero⁴, Fernando Sánchez-Alonso⁵ and Joaquin Maria Belzunegui-Otano⁶, ¹Rheumatology Department, Donostia University Hospital, San Sebastian-Donostia, Pais Vasco, Spain, ²Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³Rheumatology Department, Donostia University Hospital., San Sebastián, Pais Vasco, Spain, ⁴Spanish Society of Rheumatology, Madrid, Spain, ⁵Sociedad Española de Reumatología, Madrid, Spain, ⁶Rheumatology Department, Donostia University Hospital., San Sebastian-Donostia, Spain
Background/Purpose: Baricitinib, a selective JAK1/JAK2 inhibitor, has demonstrated efficacy in rheumatoid arthritis (RA). In patients with stable disease control for at least six months, reducing…
Abstract Number: 1102 • ACR Convergence 2025
Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Julia Barasch¹, Nilasha Ghosh², Deanna Jannat-Khah³, Kyle Ge⁴, Jeffrey Curtis⁵ and Anne R. Bass³, ¹NYP- Weill Cornell, New York, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: New onset inflammatory arthritis (IA) is reported in 6% of patients who receive immune checkpoint inhibitors (ICI). We previously developed an administrative claims-based algorithm…
Abstract Number: 2133 • ACR Convergence 2025
Examination of HLA-DRB1*15-linked Candidate Antigens in Still’s Disease with and without Lung Disease and Features of Drug Hypersensitivity
Dale Kobrin¹, Garrett Brown², Mariana Correia Marques¹, Carol Lake³, Michelle Millwood⁴, Lisa Workman⁵, Monica Lawrence⁵, Zuoming Deng⁶, Sanchita Das² and Michael Ombrello⁷, ¹Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, ³NIH, GAITHERSBURG, MD, ⁴National Institutes of Health (NIH), Bethesda, MD, ⁵Division of Asthma, Allergy, and Immunology, University of Virginia School of Medicine, Charlottesville, VA, ⁶Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Lung disease in systemic juvenile idiopathic arthritis and adult-onset Still’s disease (Still’s-LD) is a severe manifestation that strongly associates with features of drug hypersensitivity…
Abstract Number: 1099 • ACR Convergence 2025
Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Grace Haeun Lee¹, Gregory Challener², Janeth Yinh³, Jeffrey Sparks⁴, Kerry L. Reynolds⁵, Donald P. Lawrence⁵, Meghan J. Mooradian⁵, Ryan J. Sullivan⁵, Hyon K. Choi⁶ and Minna Kohler⁷, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Boston, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) has been recommended [1-3] as a steroid-sparing agent for immune checkpoint inhibitor-inflammatory arthritis (ICI-IA), preferred due to its low immunosuppressive effect. However,…
Abstract Number: 2118 • ACR Convergence 2025
Risks of Fracture in Current and Previous Anticonvulsant Users, An Observational Study
Grace Hyeyeon Lee¹, Hamzah Amin² and marwan Bukhari¹, ¹University Hospitals of Morecambe bay NHS foundation trust, Lancaster, United Kingdom, ²Lancaster University, Lancaster, United Kingdom
Background/Purpose: Anticonvulsants are commonly used to manage neurological and psychiatric disorders such as epilepsy, migraines and bipolar disorder. These medications are often prescribed long-term, and…
Abstract Number: 1098 • ACR Convergence 2025
Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Francisco Arias¹, Omar Hamdan², Asim Khanfar³, Kristel Barturen⁴ and Roa’a Alshajrawi⁵, ¹University of Texas Rio Grande Valley, McAllen, TX, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Rochester, NY, ⁴Universidad San Martin de Porres, McAllen, TX, ⁵University of Jordan, Amman, 'Amman, Jordan
Background/Purpose: Apremilast, a PDE-4 inhibitor, is commonly indicated for patients with psoriasis as well as Behçet’s disease. Although this medication is generally well tolerated, numerous…
Abstract Number: 2112 • ACR Convergence 2025
Which drugs are associated with the development of osteonecrosis of the jaw? clinical and epidemiological analysis of a cohort of patients diagnosed with osteonecrosis of the jaw.
Esther Monleon Acosta¹, Alicia Pérez González², José Andrés Rodríguez Fernández², Pedro José Manuel Hernández², María del Rosario Oliva Ruiz², José María Andreu Ubero², Paloma Valentina Castillo Dayer², Gloria Albaladejo Paredes³, Carlos Fernández Díaz⁴, Angela Egea Fuentes², Montserrat Fernández Salamanca² and Vicente Cogolludo Campillo⁵, ¹Hospital Santa Lucia, Cartagena, Spain, ²Hospital General Universitario Santa Lucia, Cartagena, Spain, ³Hospital General Universitario Santa Lucía, CARTAGENA, Spain, ⁴H.U. Santa Lucia, Murcia, Spain, ⁵Hospital General Universitario Santa Lucia, Santa Lucia, Cartage, Spain
Background/Purpose: Osteonecrosis of the jaw (ONJ) is defined as avascular necrosis of bone located in the maxillofacial region with the presence of exposed bone or…
Abstract Number: 1097 • ACR Convergence 2025
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Elvis Hysa¹, Andrea Casabella², Emanuele Gotelli³, Rosanna Campitiello⁴, Carlo Genova⁴, Enrica Teresa Tanda⁴, Carmen Pizzorni⁵, Alberto Sulli⁵, Vanessa Smith⁶, Marco Amedeo Cimmino⁷, Sabrina Paolino⁵ and Maurizio Cutolo⁴, ¹University of Genoa, Genoa, Italy, ²IRCCS Ospedale Policlinico San Martino, Genova, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genova, Genova, Italy, ⁵University of Genoa, Genova, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷Rheumatology Outpatient Clinic, Villa Ravenna, Chiavari, Italy, Genova, Italy
Background/Purpose: An altered immune tolerance disturbed by immune checkpoint inhibitors (ICIs) may contribute to new-onset polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in treated…
Abstract Number: 1985 • ACR Convergence 2025
Identifying Gaps in Documented Contraception Counseling and Gynecology Referrals for Women on Teratogenic DMARDs: A Foundation for EMR-Based Quality Improvement
Rachel Galvao, Anokhi Saklecha, Julia Stevenson, Ritche Hao, Eugenia Chock and Abhijeet Danve, Yale University, New Haven, CT
Background/Purpose: Teratogenic medications are commonly prescribed to women of reproductive age who have rheumatic conditions. Counseling on teratogenicity and contraception is critical to reducing patients’…
Abstract Number: 1092 • ACR Convergence 2025
Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Binod Kc¹, Aakritee Sharma Subedi¹, Salome Walsh¹, Areeba Memon¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the immune system's ability to fight cancer. However, their use is associated with immune-related…
Abstract Number: 1979 • ACR Convergence 2025
Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis
Julia Wajsberg¹, Dana Nachawati², Lenche Kostadinova³, Donald Anthony⁴ and Maya Mattar³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland, ³Louis Stolkes Cleveland VA, Cleveland, ⁴The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Methotrexate (MTX) is widely used in rheumatologic disease but carries hepatotoxic risk. Standard monitoring relies on measurement of alanine and aspartate aminotransferase (ALT and…

1
2
3
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].